Trials / Completed
CompletedNCT01775631
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma
Detailed description
Intervention model: Dose Escalation (part 1) of study= Sequential Design; Dose Expansion (part 2) of study= Parallel Design
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Urelumab | |
| BIOLOGICAL | Rituximab |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2013-01-25
- Last updated
- 2017-03-31
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01775631. Inclusion in this directory is not an endorsement.